PT - JOURNAL ARTICLE AU - Geier, Christian AU - Qudsi, Haani AU - Gabr, Jihad Ben AU - Winchester, Robert AU - Perl, Andras TI - CD1c Dendritic Cells are depleted and accompanied by new HLA-DR<sup>hi</sup> Phenotypes in Rheumatoid Arthritis Blood AID - 10.1101/2024.03.13.24304213 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.13.24304213 4099 - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304213.short 4100 - http://medrxiv.org/content/early/2024/03/15/2024.03.13.24304213.full AB - Rheumatoid arthritis (RA) in an autoimmune disease that leads to inflammation of synovial joints and other organs. Many RA patients ‘share’ a common peptide sequence within the HLA-DR (DR) molecule expressed on antigen-presenting cells (APC), suggesting that DRhi cells are important in RA. Here, we use DRhi to broadly define and immunophenotype RA APC, including potential APC not meeting standard definitions for lymphocytes, monocytes, dendritic cells (DC) from RA patients and healthy controls (HC). We measured mean fluorescence intensities (MFI) of molecules associated with DC (CD141, CD1c, CD11c, CD123, CD303), monocytes (CD14, CD16); granulocytic markers (CD15, CCR3), co-stimulatory molecules and chemokine receptors. DC2 (CD1c+) showed higher CD56, CD86, CD275, and CCR7 in RA. DC2 frequencies were much lower in RA: 3.2% of DRhi [IQR 2.41 to 4.46] in RA vs. 6.9% [IQR 3.96 to 9.08] in HC; p=0.005. CD15 was increased in all RA APC subsets (p&lt;0.01). A distinct CD15+CD16+ population appeared in RA, representing 1.5% of leukocytes [IQR 0.68 to 3.32] (vs 0.1% in HC [IQR 0.08 to 0.46]; p&lt;0.001) and contributed a mean of 2.34% to overall DRhi. The CD15+CD16+ subset was CD303+, CD83+ and CD275+ with much less CD123 relative to reference plasmacytoid DC (p&lt;0.01). In conclusion, APC alterations in RA include depletion of DC2 and increased CD15. Moreover, the APC (DRhi) compartment in RA contains cells with shared dendritic cell and granulocytic features; this phenotype suggests these apparent APC may participate in the pathophysiology of rheumatoid arthritis via the presentation of self-antigen(s) to CD4+ T lymphocytes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGrant funding for the work reported in this manuscript was provided by the Ines Mandl Research Foundation and SUNY Upstate Medical University (Department of Medicine); commercial sources were not involved.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of SUNY Upstate Medical University (Syracuse, USA) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes